Everyone only ever shows their winners, but let's be honest - that's boring.

I'm going to turn the tables and present you with my own personal financial disasters. Because who diamond hands need a thick skin.

My investment strategy?

• Hold for at least Hold for 5-10 years (i.e. enough time to ride out a complete market crisis).
• A maximum of 1% of the portfolio in speculative stocks (haha, if only that were the case).
• No stop loss, because I prefer to look straight into the abyss.

Here are my highlights from the "Let's burn down the portfolio!"-category:

Intel (-41%) $INTC (-7.3%)

I thought I was buying a solid chip giant. Turns out: I bought a museum walk through the glory days of 1995. While Nvidia is flying to the moon, Intel is barely keeping its head above water like an old Windows 98 computer.

Unity Software (-68%) $U (+2.89%)

"Gaming is the future! Unity is THE platform for developers!" - At least that's what I thought. In reality, Unity has bugged itself so badly that not even a game patch would help. At least I have the consolation that my shares are more lag than a mobile game with too much advertising.

Walgreens Boots Alliance (-77%) $WBA

Pharmacies? Safe bet! People always get sick! It's just stupid when a company is managed in such a way that even a pharmaceutical giant looks like it has overdosed itself.

Compass Pathways (-88%) $5Y6A

Psychedelic therapy is the future! Or so I thought. But my investment journey was more like a wild drug trip that ended directly in the financial hole. Instead of astral travel, it was just capital destruction.

Edita's Medicine (-95%) $EDIT (+3.18%)

Genetic engineering and CRISPR? Technology of the future! It's just a shame that my investment was deleted faster than faulty DNA. Editas has actually managed to edit itself out - and my capital along with it.

And you?

Do you also have a "Loss P0rn" story you want to share?

Or are you smarter than me and use stop losses? 😂

Editas Medicine: CRISPR technology with great potential

• Editas Medicine has entered into a license agreement with Vertex Pharmaceuticals for the development of CRISPR/Cas9-based therapies for Duchenne muscular dystrophy.
• Editas Medicine has a strong pipeline portfolio with several promising candidates in clinical development.
• Conclusion: Editas Medicine is a good buy for investors interested in the future of CRISPR technology.

Hi to All,

I would like to share with you my portfolio.

In terms of structure, I can say that I am heavily invested in the healthcare sector, which is certainly due to my profession. With $VRTX (+0.88%) and $REGN (+0.69%) I have largely stable companies in the portfolio. In addition, there are employee shares in the portfolio, which are allocated over the years. With $AXSM (+1.9%) and $BTAI I have two up-and-coming companies that have recently launched their first product and have an interesting pipeline for me. I have sold some shares in these companies recently to take some pressure off my portfolio, as it was very dependent on Axsome, for example. Otherwise you can still discover some exciting growth stocks ($NTLA (-1.48%) , $EDIT (+3.18%) , $ALEC (+3.15%) )

At the moment, I am focusing on diversifying more in the different sectors and choosing stocks that offer more support in this time of crisis. Therefore my choice is BlackRock, Pepsi, BASF, BHP and some others. (Even if BASF is stumbling a bit at the moment) In parallel, some stocks with dividends, which are always reinvested.

I am aware that my portfolio is not yet ideally structured, but I am currently working on it. Focus at the moment is on $PEP (+0.08%)
$ZTS (-0.37%)
$BLK . On my watchlist I have at the moment $DHR (+0.06%) or $TMO (+0.74%) as equipment manufacturer and distributor in the life science sector as well as $PG (-0.4%) for the consumer staples sector.

Finally, about myself 30 years, 2 kids, living separately. Goal: A deposit for old age

Savings rate currently: 200 to 250 euros + dividends.

My personal weakness:

I find it difficult to invest in an ETF to build this as a core.

Looking forward to the feedback.

Change of strategy

Very interesting company in the field of gene editing. Buy once. Accordingly, I won't be adding any more. this will probably be an all-or-nothing candidate in my portfolio 😁